Trtl-913

Phase 2

TTortugas Neuroscience, Inc.

Trtl-913 is one of 14 therapeutic programs targeting Tinnitus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

TinnitusNot yet recruiting

TinnitusPhase 2

Not yet recruiting

Competition

Competitive Landscape

14 competitors in Tinnitus

#DrugCompanyPhaseTrials

Levitra

Bayer

Approved

—2

Decadron

AAspen Global Incorporated

Approved

1 3

Xylocaine

MMEDRx USA, Inc.

Approved

—4

Paxil

SSebela Pharmaceuticals Development LLC

Enbrel

1 6

Pletal

Otsuka

Preclinical

1 7

Rayos

RRoxane Laboratories

Preclinical

1 8

IV Lidocaine

WWake Forest University Health Sciences

Phase 1

1 9

Trtl-913

TTortugas Neuroscience, Inc.

Phase 2

1 10

Syntocinon

SShana McCormack, MD

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Not yet recruiting

Tinnitus

NCT07777549

Clinical

Trials by Indication[1]

Tinnitus1 trial

A Phase 2a, Randomized, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TRTL-913 in Healthy Adult Volunteers Under Fed Conditions (Part A), and an Open-Label Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy in Adults With Tinnitus (Part B)

Not yet recruiting·TTortugas Neuroscience, Inc.·Phase 2·NCT07777549·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Trtl-913. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Trtl-913. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Tortugas Neuroscience, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: TTortugas Neuroscience, Inc.

Trtl-913

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Tinnitus1 trial

References

Drug Info

Quick Facts

Related News